PMID- 35072907
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20230112
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 115
IP  - 3
DP  - 2022 Mar
TI  - Clinical impacts of frailty, poor performance status, and advanced age in 
      carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post 
      hoc investigation of the KOTOSG multicenter pilot prospective observational 
      study.
PG  - 350-362
LID - 10.1007/s12185-021-03262-z [doi]
AB  - We conducted a post hoc analysis of our previous pilot observational study on the 
      efficacy and safety of carfilzomib (CFZ)-containing therapy in 50 patients with 
      relapsed/refractory multiple myeloma in routine practice to clarify the 
      relationships between three major criteria for vulnerability (frailty, poor 
      performance status [PS], and advanced age [>/= 75 years]) and their clinical impact 
      on efficacy and adverse events (AEs). Sixteen patients fulfilled at least one and 
      five patients fulfilled all three criteria. The overall response rate was not 
      significantly affected by frailty, poor PS, and/or advanced age; however, frailty 
      and advanced age were significantly associated with shorter progression-free 
      survival (PFS). In contrast, no significant difference in PFS was observed 
      between patients with PS0-1 or PS2-4. The three criteria for vulnerability were 
      associated with more frequent hematologic AEs: frailty, poor PS, and/or advanced 
      age significantly increased the risk of grade 3-4 anemia and lymphopenia. 
      However, these criteria were not associated with increased risk of other 
      non-hematologic AEs except infection. Collectively, these results demonstrate the 
      need to carefully manage severe hematologic AEs in vulnerable patients and 
      perform disease-specific assessment of frailty to predict prognosis.
CI  - (c) 2022. Japanese Society of Hematology.
FAU - Kawaji-Kanayama, Yuka
AU  - Kawaji-Kanayama Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Muramatsu, Ayako
AU  - Muramatsu A
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Sasaki, Nana
AU  - Sasaki N
AD  - Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
FAU - Shimura, Kazuho
AU  - Shimura K
AD  - Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan.
FAU - Kiyota, Miki
AU  - Kiyota M
AD  - Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
FAU - Fuchida, Shinichi
AU  - Fuchida S
AD  - Department of Hematology, Japan Community Health Care Organization, Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Isa, Reiko
AU  - Isa R
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Fujino, Takahiro
AU  - Fujino T
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Matsumura-Kimoto, Yayoi
AU  - Matsumura-Kimoto Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Tsukamoto, Taku
AU  - Tsukamoto T
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Chinen, Yoshiaki
AU  - Chinen Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Mizutani, Shinsuke
AU  - Mizutani S
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Nakao, Mitsushige
AU  - Nakao M
AD  - Department of Internal Medicine, Otsu Municipal Hospital, Otsu, Japan.
FAU - Kaneko, Hiroto
AU  - Kaneko H
AD  - Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan.
FAU - Kawata, Eri
AU  - Kawata E
AD  - Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
FAU - Hirakawa, Koichi
AU  - Hirakawa K
AD  - Department of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan.
FAU - Takahashi, Ryoichi
AU  - Takahashi R
AD  - Department of Hematology, Omihachiman Community Medical Center, Omihachiman, 
      Japan.
FAU - Shimazaki, Chihiro
AU  - Shimazaki C
AD  - Department of Hematology, Japan Community Health Care Organization, Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Uchiyama, Hitoji
AU  - Uchiyama H
AD  - Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, 
      Japan.
FAU - Uoshima, Nobuhiko
AU  - Uoshima N
AD  - Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
FAU - Shimura, Yuji
AU  - Shimura Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
AD  - Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Kyoto, 
      Japan.
FAU - Kobayashi, Tsutomu
AU  - Kobayashi T
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
FAU - Taniwaki, Masafumi
AU  - Taniwaki M
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
AD  - Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan.
AD  - Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University 
      of Medicine, Kyoto, Japan.
FAU - Kuroda, Junya
AU  - Kuroda J
AUID- ORCID: 0000-0001-6130-1550
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. 
      junkuro@koto.kpu-m.ac.jp.
CN  - Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
LA  - eng
PT  - Journal Article
DEP - 20220124
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Oligopeptides)
RN  - 72X6E3J5AR (carfilzomib)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Female
MH  - Frailty/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Multiple Myeloma/*drug therapy/mortality
MH  - Neoplasm Recurrence, Local
MH  - Observational Studies as Topic
MH  - Oligopeptides/*adverse effects/therapeutic use
MH  - Pilot Projects
MH  - Prognosis
MH  - Prospective Studies
MH  - Psychomotor Performance/*drug effects
MH  - Risk
MH  - Safety
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Advanced age
OT  - Carfilzomib
OT  - Frailty
OT  - Multiple myeloma
OT  - Performance status
EDAT- 2022/01/25 06:00
MHDA- 2022/03/11 06:00
CRDT- 2022/01/24 12:14
PHST- 2021/10/01 00:00 [received]
PHST- 2021/11/14 00:00 [accepted]
PHST- 2021/11/12 00:00 [revised]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2022/01/24 12:14 [entrez]
AID - 10.1007/s12185-021-03262-z [pii]
AID - 10.1007/s12185-021-03262-z [doi]
PST - ppublish
SO  - Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 
      2022 Jan 24.